Evofem Biosciences, Inc. (EVFM) bonds
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Evofem Biosciences reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Evofem Biosciences's 10-Q for the period ended Jun 30, 2026
| Issue | Matures | Amount issued | Carrying value |
|---|---|---|---|
| Aditxt April Notes | Apr 8, 2028 | $2.31M | – |
| Aditxt June Notes | Jun 26, 2028 | $1.42M | – |
| Adjuvant Notes Convertible at $26 a share | – | $22.50M | $34.01M |
| Baker Bros Notes Convertible at $4.58K a share | – | $25.00M | – |
| Senior Subordinated Notes | – | $14.72M | – |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?